Current aging science最新文献

{"title":"Plant-derived Secondary Metabolites that Delay Dermal Aging in Humans Through Longevity Pathways.","authors":"Nipuni Dilanka Hennadige, Thisanja Cooray, Shalini Wijerathne, Nishadi Rathnayake, Sanadie Gamage, Nirmal Perera, Umapriyatharshini Rajagopalan, Poorna Piyathilake, Kamani Tennekoon, Prasanna Galhena, Kanishka Senathilake, Sameera R Samarakoon","doi":"10.2174/0118746098392593251129081229","DOIUrl":"https://doi.org/10.2174/0118746098392593251129081229","url":null,"abstract":"<p><p>Skin is the largest organ of the human body and is one of the organs most affected by aging, contributing to the appearance associated with old age. Skin aging, also known as dermal aging, is influenced by both genetic and environmental factors. Plant secondary metabolites provide a potent source of diverse natural compounds with many pharmaceutical and biological activities, which offer promising anti-aging benefits. These plant-derived secondary metabolites have the potential to delay or decrease dermal aging by modulating key molecular players such as MMP, p53, p21, mTOR, and TGF-β. Activation or deactivation of these molecular players may accelerate or decelerate the aging process, respectively, and thereby exert direct effects on longevity. This narrative review begins with an introduction to the basic cellular concepts of dermal aging, then delves into the hallmarks of aging and discusses the different types of known plant-derived secondary metabolites, highlighting the mechanisms by which they delay dermal aging.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147834672","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Association between Primary Hypercholesterolemia, Including Familial Hypercholesterolemia, and Abdominal Aortic Aneurysm in the General Population: Results of NDB-K7Ps-Study-5.","authors":"Kei Nakajima, Airi Sekine","doi":"10.2174/0118746098418266260116211524","DOIUrl":"https://doi.org/10.2174/0118746098418266260116211524","url":null,"abstract":"<p><strong>Introduction: </strong>Patients with primary hypercholesterolemia (PH), including familial hypercholesterolemia (FH), are at elevated risk for cardiovascular disease. However, the associations between PH, FH, and aortic aneurysm, a life-threatening condition, remain unclear. This study aimed to investigate these associations in a general population using the Japanese National Database.</p><p><strong>Methods: </strong>We reviewed the data of 8,995,522 individuals aged 40-74 years who underwent annual health checkups. PH, including heterozygous/homozygous (definite FH) and non-classified FH (probable FH), chest aortic aneurysm (CAA), and abdominal aortic aneurysm (AAA), were determined based on medical insurance claim codes.</p><p><strong>Results: </strong>The prevalence of PH, including definite (n = 436) and probable FH (n = 2,857), was 0.18% (n = 16,338) in total. CAA and AAA accounted for 0.16% (n = 26) and 0.45% (n = 73) in PH patients, and 0.05% and 0.09% in non-PH patients, respectively. Among PH, non-FH, including familial-combined hyperlipidemia, and definite/probable FH were significantly associated with AAA even after adjusting for confounders, including pharmacotherapies for hypertension, diabetes, and dyslipidemia [ORs and 95% CIs, 1.96 (1.53-2.53) and 4.25 (2.33-7.44), both p <0.001].</p><p><strong>Discussion: </strong>This study explored significant associations between PH, FH, and aortic aneurysms, specifically AAA, all of them were rare in the general population, which was barely disclosed using the data of 9 million people who underwent regular checkup.</p><p><strong>Conclusion: </strong>PH and FH were associated with aortic aneurysms, particularly AAA, even in the research of the general population.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147721886","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Impact of Cognitive Behavioral Group Therapy with or without Lavender Aroma on Sleep Quality in Menopausal Women: Randomized Controlled Trial.","authors":"Arezoo Shayan, Leilli Tapak, Mahttab Satari, Raziyeh Dalvand, Fariba Bigdelimojarad, Shirin Moradkhani, Azita Tiznobaik","doi":"10.2174/0118746098434021260107062622","DOIUrl":"https://doi.org/10.2174/0118746098434021260107062622","url":null,"abstract":"<p><p>Introduction/ Objective: Menopause and the decrease in estrogen levels have numerous negative effects on sleep quality and mental health in women, potentially leading to anxiety and irritability. Non-pharmacological treatments have gained attention as alternative methods for improving sleep quality. This study aimed to evaluate the effectiveness of Cognitive Behavioral Group Therapy (CBGT) with or without lavender aroma on sleep quality in post-menopausal women.</p><p><strong>Methods: </strong>This randomized controlled trial (RCT), double-blind, enrolled 135 eligible menopausal women from health centers in Hamadan, Iran, between 2022 and 2023. Participants were randomly assigned to three groups: CBGT with placebo, CBGT with lavender aroma, and a control group. The intervention consisted of eight 60-90-minute CBGT sessions over one month for the first two groups, with placebo or lavender aroma administered. Sleep quality was assessed using the Pittsburgh Sleep Quality Index (PSQI) before and after the intervention. Data were analyzed using SPSS version 21, with statistical significance set at p < 0.05.</p><p><strong>Results: </strong>Participants had a mean age of 60.1 ± 5.9 years and a menopause duration of 3.1 ± 1.2 years. In the CBT with lavender group, 79.1% achieved good sleep quality (PSQI ≤ 5) postintervention (p = 0.001), with significant improvements in subjective sleep quality (p = 0.001), sleep duration (p = 0.001), and sleep efficiency (p = 0.001), and reductions in sleep latency (p = 0.001) and sleep disturbances (p = 0.001). No significant improvements were observed in the CBT with placebo or control groups (p > 0.05).</p><p><strong>Conclusions: </strong>Combining CBGT with lavender aromatherapy is an effective nonpharmacological approach to improve sleep quality in menopausal women, potentially reducing reliance on pharmacotherapy and its associated side effects.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-04-09","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147670782","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Investigating the Potential of Gene Editing Technologies in Enhancing Stem Cell Therapy for Alzheimer's Disease.","authors":"Shima Mehrabadi","doi":"10.2174/0118746098414335251203135400","DOIUrl":"https://doi.org/10.2174/0118746098414335251203135400","url":null,"abstract":"<p><p>Alzheimer's disease (AD) is a complex neurodegenerative disorder characterized by progressive cognitive decline and memory loss, significantly affecting the quality of life for millions of people worldwide. Current therapeutic options primarily focus on symptomatic relief, with limited effectiveness in addressing the underlying pathophysiology. Recent advancements in gene editing technologies, particularly CRISPR/Cas9 (Clustered Regularly Interspaced Short Palindromic Repeats), offer promising opportunities to enhance stem cell therapy for AD. This review explores the potential of gene editing to target genetic risk factors associated with AD, such as APOE4 (Apolipoprotein E) and TREM2 (Triggering Receptor Expressed on Myeloid Cells 2), and to improve the differentiation and functionality of induced pluripotent stem cells (iPSCs) derived from AD patients. By creating more accurate disease models and humanized animal systems, researchers can gain a deeper understanding of the mechanisms of AD and evaluate novel therapeutic strategies. Moreover, combining gene editing with stem cell therapy may facilitate cell replacement therapies and the development of exosome-based treatments that modulate neuroinflammation and promote neuroprotection. Despite the promise of these approaches, challenges, such as off-target effects, delivery efficiency, and ethical considerations, remain significant hurdles. This review aims to provide a comprehensive overview of the current state of research, emphasizing the potential of gene editing technologies to revolutionize stem cell therapy for AD and improve patient outcomes.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-31","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Invisible Threats of Microplastics as a New Frontier in Gerontology.","authors":"Gunvanti Rathod, Pragnesh Parmar","doi":"10.2174/0118746098435698260119074225","DOIUrl":"https://doi.org/10.2174/0118746098435698260119074225","url":null,"abstract":"<p><p>Specifically, microplastics are defined as those particles that measure less than 5 millimeters in diameter. Certainly, microplastic particles are now present in the global environment. It has been observed that they are present in the air that we breathe, the water that we drink, and the food that we eat. Recent research studies revealed that microplastic particles are also present in the human body. Currently, new evidence has shown that microplastic particles are not only widespread but also responsible for causing various types of biological damage. The biological damage caused by microplastic particles includes oxidative stress, effects on cell energy metabolism, promotion of inflammation, and effects on the immune system, all of which are associated with aging. Recent research has identified that microplastic particles are present in various parts of the human body, including the placenta, blood, lungs, and brain. Furthermore, microplastics have been associated with causing various forms of age-related diseases, as well as neurodegenerative, cardiovascular, metabolic, and reproductive diseases. The aim of this mini-review is to summarize current knowledge regarding microplastics and aging while acknowledging existing knowledge gaps. Future research should focus on improving exposure assessment methods and conducting long-term human studies to better understand the potential role of microplastics in aging and age-related diseases.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147608139","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Relationship between Serum Fractalkine (CX3CL1) Level and Sarcopenia.","authors":"Demet Yilmaz, Rasim Mogulkoc, Gozde Acar, Merve Yilmaz Kars, Muhammed Cemal Kizilarslanoglu, Abdulkerim Kasim Baltaci","doi":"10.2174/0118746098432989251203211700","DOIUrl":"https://doi.org/10.2174/0118746098432989251203211700","url":null,"abstract":"<p><strong>Introduction: </strong>Aging affects muscle mass, bone mineral density, and fat tissue, causing changes in body composition. Preserving muscle mass, as well as muscle function and strength, is important for individuals to be independent in daily life activities and to be able to do their work in old age. The current study aimed to determine the changes that may occur in fractalkine levels in sarcopenic individuals.</p><p><strong>Methods: </strong>The research was conducted between April and October 2024 on individuals aged 60 and over who applied to the Geriatrics Polyclinics of SBU Konya City Hospital and agreed to participate in the research. The groups in the study were composed of healthy controls, probable sarcopenic, sarcopenic, and severe sarcopenic patients.</p><p><strong>Results: </strong>A significant decrease was determined in both muscle mass and hand grip strength in sarcopenic patients compared to healthy controls. At the same time, sarcopenic patients have low fractalkine values.</p><p><strong>Discussion: </strong>The results of the current study indicate that sarcopenic patients experience significant decreases in physical performance due to a decline in muscle mass. In addition, suppression was detected in the values of fractalkine, a myokine secreted from muscle, in the patients in question.</p><p><strong>Conclusion: </strong>The study's results show that decreasing muscle mass with age causes a significant decrease in serum fractalkine levels.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147644516","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Recent Alzheimer's Research Targets Amyloid-β with Novel Phytochemicals and Pharmacological Strategies for Therapy.","authors":"Shikha Sharma, Utkarsh Sharma, Neeraj K Sethiya, Lakshit Singh","doi":"10.2174/0118746098373086251201095903","DOIUrl":"https://doi.org/10.2174/0118746098373086251201095903","url":null,"abstract":"<p><p>Advances in molecular-level research proposed the Amyloid-β (Aβ) pathway as a pathophysiological centre of Alzheimer's Disease (AD) progression. The biochemical alterations within the Aβ cycle represent a core biological hallmark of AD and offer promising targets for the development of disease-modifying therapies. However, the precise molecular mechanisms of the Aβ pathway, as well as the spatial and temporal dynamics that drive synaptic dysfunction, neurodegeneration, and the clinical onset of AD, remain active and intensive current research areas. In this work, we provide a comprehensive review and update of the extensive body of research in the field. We analyze data that highlights the differential relationships between various species of Amyloid-β (Aβ) and several biological mechanisms relevant to Alzheimer's Disease (AD), including tau-mediated processes, neuroimmune responses, inflammatory changes, and neurochemical imbalances. This review explores the role of amyloid β, clinical symptoms and mortality, FDA-approved drugs, immunotherapy, and different phytoconstituents used for Aβ-targeting therapy. Phytochemicals show potential in Alzheimer's disease treatment through their antioxidant, anti-inflammatory, and anti-amyloid properties, but challenges with bioavailability and blood-brain barrier permeability remain significant obstacles to their clinical effectiveness.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2026-03-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"147442770","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Dual Approaches for Parkinson's Disease: Role of the Dopaminergic and Non-Dopaminergic Therapies.","authors":"Brijesh Kumar Duvey, Ravneet Singh Sumbel, Abhishek, Devkant Sharma, Anurag Bhargava, Vishnu Mittal, Anjali Sharma","doi":"10.2174/0118746098382353251012173313","DOIUrl":"https://doi.org/10.2174/0118746098382353251012173313","url":null,"abstract":"<p><p><p> Introduction: Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by both motor and non-motor symptoms, primarily due to the degeneration of dopaminergic neurons. This review aims to explore the therapeutic landscape of PD, focusing on dopaminergic and non-dopaminergic treatment strategies, as well as recent advancements and future directions in managing the disease. </p><p> Methods: A comprehensive literature review was conducted using databases such as PubMed, Science Direct, and Scopus, covering studies published up to 2025. The review focused on epidemiological trends, pathophysiological mechanisms, diagnostic approaches, and pharmacological and non-pharmacological therapies related to PD. </p><p> Results: PD affects approximately 1-2% of individuals over 60 years of age, with its prevalence expected to rise globally. Motor symptoms such as bradykinesia, rigidity, and tremor are wellrecognized, but non-motor symptoms remain underdiagnosed. Dopaminergic therapies, including levodopa and dopamine agonists, are effective in symptom management but are associated with long-term complications. Non-dopaminergic approaches, such as MAO-B inhibitors, amantadine, anticholinergics, and deep brain stimulation, offer additional symptom control. Emerging strategies include gene therapy, immunotherapy, and neuroprotective agents targeting disease modification. </p><p> Discussion: While current treatments provide symptomatic relief, they do not halt disease progression. A multidimensional therapeutic approach combining dopaminergic and nondopaminergic strategies is necessary. Advances in molecular genetics and biomarker discovery hold promise for early diagnosis and personalized treatment. However, the need for more targeted, disease-modifying therapies remains a major challenge. </p><p> Conclusion: This review underscores the importance of integrating traditional and emerging therapies for comprehensive PD management. Future research should focus on genetic insights, early detection, and innovative therapeutics to improve patient outcomes and quality of life.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145511971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Behavioral and Psychological Symptoms of Dementia: A Review of its Management in Sub-Saharan Africa.","authors":"Marian Esther Miller","doi":"10.2174/0118746098386183251001145157","DOIUrl":"https://doi.org/10.2174/0118746098386183251001145157","url":null,"abstract":"<p><p>Dementia has been highlighted as one of the key diagnoses among elderly people. This study seeks to review the management of behavioral and psychological symptoms of dementia in Sub-Saharan Africa. A comprehensive review was carried out with the aid of online research journal websites as well as other in-context articles. While conducting this study, the keywords in the search query were directed towards managing behavioral and psychological symptoms of dementia in Sub-Saharan Africa. Areas noted in relation to this study were understanding the effects on management of behavioral and psychological symptoms of dementia in Sub-Saharan Africa. It was discovered that 88% of the population of Ghana and 90% of the population of South Africa do not have an idea about dementia. Health professionals in sub-Saharan Africa are not provided with the knowledge they need to take care of dementia patients. There is a high prevalence rate of dementia in Africa, with a probability of having over 200% rate in dementia due to the rise of the older generation. There is a need to address the education of dementia before the management of the behavioral and psychological symptoms of dementia can be curbed. Until that is that Africa will constantly be in a cycle of being at the verge of breakthrough in addressing the management of dementia and coming back to the root cause, which is health education.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-11-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145480739","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Repetitive Transcranial Magnetic Stimulation in Dementia.","authors":"Georgios Mikellides, Amir Arshia Emam Jomeh, Eleanor Arati Roy, Marios Kyriazis","doi":"10.2174/0118746098392580251003064940","DOIUrl":"https://doi.org/10.2174/0118746098392580251003064940","url":null,"abstract":"<p><p>Repetitive Transcranial Magnetic Stimulation (rTMS) is a non-invasive neuromodulatory technique that is increasingly being investigated for its therapeutic potential in cognitive impairment associated with dementia and Alzheimer's disease. This narrative review synthesizes and critically appraises the current evidence surrounding rTMS, with particular focus on clinical efficacy, neurobiological mechanisms, and emerging innovations. High-frequency stimulation over the Dorsolateral Prefrontal Cortex (DLPFC) has consistently demonstrated improvements in memory, executive function, and attention, likely mediated by enhanced synaptic plasticity, increased neurotrophic factor expression, and modulation of large-scale brain networks, such as the default mode and fronto-parietal networks. Recent high-quality studies have built upon earlier research to highlight the comparative efficacy of target-specific stimulation, including precuneus- and parietal-based protocols, as well as multi- site strategies that engage language and associative regions. It also examines the use of TMSEEG and DMN connectivity as predictors of treatment response, supporting a shift toward personalized, biomarker-guided rTMS paradigms. Moreover, the synergistic potential of combining rTMS with cognitive training and pharmacotherapy is explored as a promising avenue for multimodal treatment. While preliminary results are encouraging, heterogeneity in study design and stimulation parameters continues to limit the generalizability of the findings. Standardization of protocols, longterm efficacy validation, and large-scale clinical trials remain critical to translating rTMS into routine dementia care.</p>","PeriodicalId":11008,"journal":{"name":"Current aging science","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2025-10-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145408423","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}